Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162633 | 0.81 | PIK3CA (0.46) | PIK3CAMKNK1MKNK2TGFBR1TGFBR2 | |
| SCHEMBL21174856 | 0.81 | MKNK1 (0.38) | PIK3CAMKNK1MKNK2TGFBR1TGFBR2 | |
| SCHEMBL20163004 | 0.80 | ALOX5AP (0.41) | PIK3CAMKNK1MKNK2TGFBR1TGFBR2 | |
| SCHEMBL20162950 | 0.79 | BTK (0.39) | PIK3CAPIK3R1 | |
| SCHEMBL20162787 | 0.74 | BRD4 (0.36) | PIK3CAMKNK1MKNK2TGFBR1TGFBR2 | |
| SCHEMBL19249457 | 0.72 | CSNK1D (0.37) | MKNK1MKNK2TGFBR1TGFBR2CSNK1D | |
| SCHEMBL28582907 | 0.67 | CDK2 (0.40) | SCN9A | |
| SCHEMBL30827972 | 0.67 | CDK2 (0.40) | SCN9A | |
| SCHEMBL20162766 | 0.67 | DHFR (0.37) | PIK3CATGFBR1KDR | |
| SCHEMBL30538088 | 0.67 | LRRK2 (0.47) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | PIK3CA 524/4885MKNK1 4472/4885MKNK2 4629/4885 |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | PIK3CA 524/4885MKNK1 4472/4885MKNK2 4629/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | PIK3CA 524/4885MKNK1 4472/4885MKNK2 4629/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | PIK3CA 547/4885MKNK1 4474/4885MKNK2 4654/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | PIK3CA 547/4885MKNK1 4474/4885MKNK2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.